Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10483060 | Research Policy | 2014 | 14 Pages |
Abstract
We examine how R&D portfolios of drug pipelines affect pharmaceutical licensing, controlling firm size, diversity, and competition. The data collected comprises 434 license-ins and 329 license-outs closed by 54 Japanese pharmaceutical companies between 1997 and 2007. We pay special attention to stage-specific licensing by dividing the innovation process into early and late stages. Joint estimates of license-in and license-out using seemingly unrelated regressions (SUR) reveal that drug pipelines significantly affect stage-specific licensing, inducing portfolio effect that lead to smoothing drug pipelines across early and late stages.
Related Topics
Social Sciences and Humanities
Business, Management and Accounting
Business and International Management
Authors
Junichi Nishimura, Yosuke Okada,